HK1249068A1 - Therapeutic uses of berberine formulations - Google Patents

Therapeutic uses of berberine formulations

Info

Publication number
HK1249068A1
HK1249068A1 HK18108954.7A HK18108954A HK1249068A1 HK 1249068 A1 HK1249068 A1 HK 1249068A1 HK 18108954 A HK18108954 A HK 18108954A HK 1249068 A1 HK1249068 A1 HK 1249068A1
Authority
HK
Hong Kong
Prior art keywords
therapeutic uses
berberine
formulations
berberine formulations
therapeutic
Prior art date
Application number
HK18108954.7A
Other languages
Chinese (zh)
Inventor
卡爾‧奧斯卡‧布朗三世
曾博遠
林伊銀
蔡陳恩
陳志光
Original Assignee
安成生物科技股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US15/161,576 external-priority patent/US20160263092A1/en
Application filed by 安成生物科技股份有限公司 filed Critical 安成生物科技股份有限公司
Publication of HK1249068A1 publication Critical patent/HK1249068A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7015—Drug-containing film-forming compositions, e.g. spray-on
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
HK18108954.7A 2015-06-24 2018-07-10 Therapeutic uses of berberine formulations HK1249068A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562184024P 2015-06-24 2015-06-24
US15/161,576 US20160263092A1 (en) 2013-12-19 2016-05-23 Therapeutic uses of berberine formulations
PCT/US2016/039180 WO2016210230A1 (en) 2015-06-24 2016-06-24 Therapeutic uses of berberine formulations

Publications (1)

Publication Number Publication Date
HK1249068A1 true HK1249068A1 (en) 2018-10-26

Family

ID=57586436

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18108954.7A HK1249068A1 (en) 2015-06-24 2018-07-10 Therapeutic uses of berberine formulations

Country Status (13)

Country Link
EP (1) EP3313520A4 (en)
JP (1) JP2018518507A (en)
KR (1) KR20180020229A (en)
CN (1) CN107921284A (en)
AU (1) AU2016282800A1 (en)
BR (1) BR112017027897A2 (en)
CA (1) CA2990237A1 (en)
HK (1) HK1249068A1 (en)
IL (1) IL256400A (en)
MX (1) MX2018000262A (en)
RU (1) RU2733743C2 (en)
TW (1) TW201713334A (en)
WO (1) WO2016210230A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018136706A1 (en) * 2017-01-19 2018-07-26 Twi Biotechnology, Inc. Methods and pharmaceutical compositions for preventing or treating immunoinflammatory dermal disorders
JP2021506958A (en) 2017-12-13 2021-02-22 オンクォリティ ファーマシューティカルズ チャイナ エルティーディーＯｎｑｕａｌｉｔｙ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｃｈｉｎａ Ｌｔｄ． How to prevent or treat diseases associated with EGFR inhibition
EP3782618A4 (en) 2018-04-16 2022-01-26 OnQuality Pharmaceuticals China Ltd. Method for preventing or treating side effects of cancer therapy
CN109999034A (en) * 2019-02-11 2019-07-12 浙江理工大学 Oncoprotein TNIK kinases targets natural small molecule inhibitor and its application
CN109806264B (en) * 2019-04-10 2021-04-02 江苏海钥医药科技有限公司 Pharmaceutical composition and application thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7404967B2 (en) * 1994-12-21 2008-07-29 Cosmederm, Inc. Topical product formulations containing strontium for reducing skin irritation
US5760096A (en) * 1996-10-18 1998-06-02 Thornfeldt; Carl R. Potent penetration enhancers
KR100258849B1 (en) * 1998-04-24 2000-08-01 박원배 Pharmaceutically useful protoberberine derivative and its salts
EP1080719A3 (en) * 1999-09-03 2001-04-25 Active Organics Inc. Methods for potentiation of efficacy of topical actives by mono-acyl-(lyso)-glycerophosholipids
US6440465B1 (en) 2000-05-01 2002-08-27 Bioderm, Inc. Topical composition for the treatment of psoriasis and related skin disorders
US9211259B2 (en) * 2002-11-29 2015-12-15 Foamix Pharmaceuticals Ltd. Antibiotic kit and composition and uses thereof
US20040146539A1 (en) 2003-01-24 2004-07-29 Gupta Shyam K. Topical Nutraceutical Compositions with Selective Body Slimming and Tone Firming Antiaging Benefits
US7205006B2 (en) * 2003-09-25 2007-04-17 Prime Pharmaceutical Corporation Mahonia aquifolium extract, extraction process and pharmaceutical composition containing the same
ATE548022T1 (en) 2003-11-17 2012-03-15 Sederma Sa COMPOSITIONS CONTAINING A COMBINATION OF TETRAPEPTIDES AND TRIPEPTIDES
US20050158404A1 (en) 2003-11-18 2005-07-21 Goodless Dean R. Composition and method for treatment of acne
WO2011000218A1 (en) * 2009-06-30 2011-01-06 Shuen-Lu Huang Compositions containing berberine or analogs thereof for treating rosacea or red face related skin disorders
TW201538156A (en) 2013-12-19 2015-10-16 Twi Biotechnology Inc Berberine formulations and uses thereof

Also Published As

Publication number Publication date
RU2018102700A (en) 2019-07-25
WO2016210230A1 (en) 2016-12-29
BR112017027897A2 (en) 2018-08-28
KR20180020229A (en) 2018-02-27
CN107921284A (en) 2018-04-17
EP3313520A1 (en) 2018-05-02
IL256400A (en) 2018-02-28
RU2018102700A3 (en) 2019-12-03
MX2018000262A (en) 2018-03-08
AU2016282800A1 (en) 2018-02-01
JP2018518507A (en) 2018-07-12
RU2733743C2 (en) 2020-10-06
EP3313520A4 (en) 2019-01-02
CA2990237A1 (en) 2016-12-29
TW201713334A (en) 2017-04-16

Similar Documents

Publication Publication Date Title
HK1254525A1 (en) Therapeutic compositions, combinations, and methods of use
HK1247614A1 (en) Therapeutic compounds and uses thereof
HK1258062A1 (en) Methods of administering elagolix
IL258997B (en) Honey-cannabinoid therapeutic composition
HK1232137A1 (en) Therapeutic compounds and compositions
HK1259372A1 (en) Therapeutic compounds, compositions and methods of use thereof
PL4070788T3 (en) Pharmaceutical formulations
HK1254343A1 (en) Pharmaceutical formulations
HK1248697A1 (en) Therapeutic compounds and uses thereof
HK1249068A1 (en) Therapeutic uses of berberine formulations
IL285882A (en) Therapeutic uses of l-4-chlorokynurenine
ZA201802256B (en) Compounds and therapeutic uses thereof
IL262745A (en) Improved drug formulations
GB201502412D0 (en) Therapeutic use
IL272857A (en) Formulations of copanlisib
IL254794A0 (en) Pharmaceutical formulations
EP3265177C0 (en) Formulations of hydrophilic compounds
IL267279A (en) Pharmaceutical formulations of suvorexant
HK1258765A1 (en) Therapeutic compounds, compositions and methods of use thereof
PT3678644T (en) Formulations of copanlisib
GB201506786D0 (en) Therapeutic use
GB201609903D0 (en) Therapeutic compositions
GB201512635D0 (en) Uses of therapeutic compounds
GB201911521D0 (en) Therapeutic agent
GB201516109D0 (en) Therapeutic agent